• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Faulkner Robert C.

    3/13/24 5:18:19 PM ET
    $SNCE
    Computer Software: Prepackaged Software
    Technology
    Get the next $SNCE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Faulkner Robert C.

    (Last) (First) (Middle)
    C/O REDMILE GROUP, LLC ONE LETTERMAN
    DRIVE, BUILDING D SUITE D3-300

    (Street)
    SAN FRANCISCO CA 94129

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Science 37 Holdings, Inc. [ SNCE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    Officer (give title below) X Other (specify below)
    Former Director
    3. Date of Earliest Transaction (Month/Day/Year)
    03/12/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/12/2024 U 26,791(1)(2) D $5.75 0 D(4)(5)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options (Right to Buy) $201 03/12/2024 D 2,068(1)(3) (3) (3) Common Stock 2,068 (1) 0 D(4)(5)
    Explanation of Responses:
    1. The reported securities were disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 28, 2024, among the Issuer, eMed, LLC, a Delaware limited liability company ("Parent"), and Marlin Merger Sub Corporation, a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for all outstanding shares of the Issuer's common stock ("Common Stock") at a purchase price of $5.75 per share, without interest and subject to applicable withholding taxes (the "Offer Price"), which such tender offer expired on March 11, 2024. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of March 12, 2024 (such date and time of such merger, the "Effective Time"). These shares of Issuer Common Stock were tendered for purchase pursuant to the tender offer.
    2. Each restricted stock unit represents a contingent right to receive one share of the Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Common Stock subject to such restricted stock unit. This number includes 24,742 unvested restricted stock units.
    3. Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
    4. The securities were granted to Mr. Faulkner in connection with his service as a member of the Board of Directors of the Issuer. Mr. Faulkner, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Faulkner held these securities as a nominee on behalf, and for the sole benefit, of Redmile and assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Faulkner has disclaimed beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Faulkner was the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    5. The securities may also have been deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green have disclaimed beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green was a beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    Remarks:
    Mr. Faulkner was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green were directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Immediately prior to the Effective Time, pursuant to the terms of the Merger Agreement, Mr. Faulkner resigned as a director of the Company, effective as of the Effective Time. On December 8, 2023, the Issuer effected a reverse stock split of its Common Stock at a ratio of 1-for-20. As a result of the reverse stock split, the shares of Common Stock, and the exercise price and shares of the Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Persons.
    /s/ Robert C. Faulkner 03/13/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SNCE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNCE

    DatePrice TargetRatingAnalyst
    11/1/2021$15.00Buy
    Lake Street
    11/1/2021$15.00Outperform
    Robert W. Baird
    11/1/2021Outperform
    William Blair
    11/1/2021$15.00Outperform
    Baird
    10/22/2021$14.00Outperform
    Cowen & Co.
    More analyst ratings

    $SNCE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial

      MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research. The inspection resulted in a No Action Indicated (NAI) categorization, with no objectionable conditions noted and no Form 483 issued. Led by Science 37's internal Quality Assurance & Compliance team, the inspection focused on the company's role in a registrational Phase 3 asthma study, which Science 37 contributed 28% of the total patient enrollment. The FDA evaluated internal processes, technology, data integrity, patien

      4/8/25 8:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

      MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company's Chief Commercial Officer, Van Horn's appointment follows his pivotal role in driving operational excellence and shaping the company's strategic direction to better prioritize client success – initiatives credited with driving growth for the company. Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing

      1/14/25 8:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

      MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, GSK. The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study. Recognizing that the available participant population for rare disease studies is often extremely limited and dispersed globally, GSK welcomed an innovative approach to expanding trial

      11/21/24 8:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Science 37 with a new price target

      Lake Street initiated coverage of Science 37 with a rating of Buy and set a new price target of $15.00

      11/1/21 9:12:40 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Robert W. Baird initiated coverage on Science 37 with a new price target

      Robert W. Baird initiated coverage of Science 37 with a rating of Outperform and set a new price target of $15.00

      11/1/21 7:43:34 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • William Blair initiated coverage on Science 37 Hldgs

      William Blair initiated coverage of Science 37 Hldgs with a rating of Outperform

      11/1/21 5:42:17 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Science 37 Holdings Inc. (Amendment)

      SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)

      3/14/24 4:17:56 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Science 37 Holdings Inc. (Amendment)

      SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)

      3/13/24 5:15:52 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Science 37 Holdings Inc. (Amendment)

      SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)

      1/31/24 5:15:22 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    Financials

    Live finance-specific insights

    See more
    • Science 37 Reports Third Quarter 2023 Financial Results

      RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter ended September 30, 2023. "Our third quarter results were highlighted by continued quarterly improvements in our key profitability metrics and cash burn rate," stated David Coman, Chief Executive Officer of Science 37. "We look forward to a strong finish to the year and positive momentum headed into 2024." Quarterly Financial Highlights Gross bookings were $17.9 million for the quarter ended September 30, 2023, a 50.6%

      11/7/23 6:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023

      RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™ today announced it will report third quarter 2023 financial results prior to the market open on Tuesday, November 7, 2023. The Science 37 management team will host a conference call to discuss these results on November 7, 2023, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-269-7751 (toll-free domestic) or 1-201-389-0908 (international) and using the Conference ID 13741458 or by utilizing the Call me™ feature using this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the i

      10/24/23 6:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 Reports Second Quarter 2023 Financial Results

      RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter ended June 30, 2023. "The actions we have taken over the past nine months are leading to meaningful improvements as evidenced by our sequential quarterly results including growth in gross bookings and gross profit margins along with a reduction in cash burn," stated David Coman, Chief Executive Officer of Science 37. "We look forward to finishing the year strong and continuing to position the company for sustainable financial growth and shareholder value creation." Quarterly Financial

      8/8/23 6:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Science 37 Holdings Inc.

      15-12G - Science 37 Holdings, Inc. (0001819113) (Filer)

      3/22/24 6:50:27 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • SEC Form EFFECT filed by Science 37 Holdings Inc.

      EFFECT - Science 37 Holdings, Inc. (0001819113) (Filer)

      3/15/24 12:15:04 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • SEC Form EFFECT filed by Science 37 Holdings Inc.

      EFFECT - Science 37 Holdings, Inc. (0001819113) (Filer)

      3/15/24 12:15:11 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Thermo Fisher Scientific Inc.

      4 - Science 37 Holdings, Inc. (0001819113) (Issuer)

      3/14/24 4:26:37 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Thermo Fisher Scientific Inc.

      4 - Science 37 Holdings, Inc. (0001819113) (Issuer)

      3/14/24 4:25:33 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • New insider Thermo Fisher Scientific Inc. claimed ownership of 17,379,797 shares (SEC Form 3) (Amendment)

      3/A - Science 37 Holdings, Inc. (0001819113) (Issuer)

      3/14/24 4:20:09 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    Leadership Updates

    Live Leadership Updates

    See more
    • Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

      MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company's Chief Commercial Officer, Van Horn's appointment follows his pivotal role in driving operational excellence and shaping the company's strategic direction to better prioritize client success – initiatives credited with driving growth for the company. Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing

      1/14/25 8:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity

      RESEARCH TRIANGLE PARK, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™, announced today Erica Prowisor as SVP of Patient and Provider Networks to accelerate patient recruitment, ensure participant diversity and gain operational efficiencies. Erica has been forging new ground as a leader in patient recruitment for nearly 20 years, most notably with IQVIA where she was Global Head of Recruitment and Retention for more than three years and led the company's direct-to-patient recruitment and retention efforts. Prior to IQVIA, Erica spent 11 years with Acurian through the acquisition by PPD where she was Head of Enrollment Opera

      4/25/23 7:59:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 Adds New Head of Quality, Irena Lambridis

      RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™, today announced the appointment of Irena Lambridis as its Global Head of Quality Assurance & Compliance. Irena will be responsible for overseeing quality and compliance across all functions, including the Company's newly announced global Centers of Excellence in India, Pakistan, and Slovakia. This key appointment reflects Science 37's commitment to quality as it expands operations globally. Irena brings nearly two decades of experience in clinical research quality assurance, having held senior leadership positions at KCR and Novella Clinical (now IQVIA

      4/18/23 7:59:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology